Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER), ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of | Roche said ...

The Trump administration is exploiting an administrative loophole to keep federal research funding frozen, despite a federal ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...

On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...

The wearable cardiac monitor maker VitalConnect has raised $100 million in new capital to aid in the development of its ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers explore cellular behavior mapped across complex tissues. | The company said ...

BioMed X Institute is teaming up with the Barbados government in an effort to accelerate cardiometabolic treatments for ...